Nelipepimut-S

DB06226InvestigationalVaccines

Investigated for use/treatment in prostate cancer and breast cancer.

Mechanism: NeuVax is a HER2/neu peptide-based T-cell immunotherapy aimed at preventing disease recurrence and prolonging survival in cancer patients that have tumors which express the HER2/neu oncoprotein. To date, clinical study results have demonstrated that NeuVax significantly reduces the rate of cancer recurrence while showing minimal side effects. [Apthera Press release]
Curator reviewed
Primary indication: Investigated for use/treatment in prostate cancer and breast cancer.Curator reviewed
Also known as: HER-2/NEU PEPTIDE (369-377) · HER2 369-377 · Human receptor tyrosine-protein kinase erbB-2 (proto-oncogene Neu, tyrosine kinase-type cell surface receptor HER2, CD340)-(347-355)-peptide · Nelipepimut S · NEUVAX
Code names: E75 · E-75 PEPTIDE

Resolves to

Compound

Targets

What you can answer from here — as of January 29, 2025

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

4Clinical trialsPhase, status and sponsor resolved per trial

3+ReferencesStructured and connected to the statements they support

Which drugs share a target with Nelipepimut-S, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.